Physician profile
Michael Reeves
NPI 1952359093
$337.72
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $338.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.33 | 2019 | |
| Shire North American Group INC | $54.43 | 2019 | |
| Abbott Laboratories | $38.93 | 2019 | |
| Insulet Corporation | $36.61 | 2019 | |
| Amgen INC. | $35.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.31 | 2019 | |
| Mannkind Corporation | $17.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.90 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$20,602.53 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.